The efficacy of intravenous phenytoin for the treatment of status epilepticus is related to the rapid entry of phenytoi brain parenchyma. There is no information concerning the correlation between phenytoin serum and CSF concentration children, and the application of CSF data to clinical use. We report 7 children (2-11 yrs) who were treated or exposed to phenytoi between 10.5-230 mg/kg. Lumbar puncture was performed 9 times in 6 of the patients. In one patient, an intraventricula catheter permitted successive assessment of CSF phenytoin concentrations. The ratio of CSF/serum phenytoin concentrations wa 0.08, with gradual increase over the first 8 hours as the serum phenytoin concentration decreased. There was good correlatio between therapeutic outcome and CSF phenytoin levels higher than 2 mcg/ml. In one patient the coma state secondary to phenytoi intoxication was associated with high CSF concentration (6 mcg/ml). RESUME: L'efficacite" du phenytoin intraiveneux dans le traitement du status Epilepticus est en rapport avec l'entr£e rapide phenytoin dans le parenchyme c6r6bral. II n'existe pas de donn6es sur la correlation entre les taux sdriques de phenytoin et ceux R chez les enfants ni sur la valeur clinique des taux dans le LCR. Nous rapportons l'6tude de 7 enfants ( e entry as the mechanism for phenytoin penetration into CSF and concluded that there is no correlation between phenytoin concentrations and seizure control. Since no data have been published concerning CSF phenytoin concentrations in the pediatric age group and its correlation the clinical outcome, we reviewed our data from 7 children received or were exposed to phenytoin and had a subse-CSF measurement carried out.
efficacy of intravenous phenytoin for the treatment of epilepticus has been established in adults (Cranford et 1979; Wilder et al., 1977) as well as in neonates (Laughman 1977; Painter et al., 1978) and children (McWilliams et al.,
The rapid entry of phenytoin into brain parenchyma n in animal studies may account for the rapid onset of phenytoin effect in controlling seizures ). d correlation has been shown between serum phenytoin concentrations and the therapeutic outcome. The range of 5-20 mcg/ml has been defined as the optimal therapeutic concentra- (Buchthal et al., 1960) . However, there are only a few s concerned with the correlation between phenytoin serum cerebrospinal fluids (CSF) concentrations. Lund (1972) demonstrated that phenytoin CSF levels are equal to the serum unbound levels of the drug. Vajda (1974) found that the CSF/plasma ratio for phenytoin was 0.12 ± 0.04. Wilder (1977) reported CSF phenytoin data for 6 adult patients, showing a gradual increase in CSF phenytoin concentrations over 50 mins the serum concentrations decreased, with a parallel decrease of the serum/CSF phenytoin ratio. Wilder suggested e entry as the mechanism for phenytoin penetration into CSF and concluded that there is no correlation between phenytoin concentrations and seizure control. Since no data have been published concerning CSF phenytoin concentrations in the pediatric age group and its correlation the clinical outcome, we reviewed our data from 7 children received or were exposed to phenytoin and had a subse-CSF measurement carried out.
MATERIAL AND METHODS
Six of the 7 patients (age range 2-11 yrs) were treated wit intravenous phenytoin eitherforestablished convulsions (patient A-D) or as a preventive measure after head trauma with com (patients E-F). One patient (G) accidentally swallowed 3g (23 mg/kg) of phenytoin, and was deeply comatose on admission There was no evidence for liver or kidney disease that migh expected to change the metabolism of phenytoin. None of patients had received other drugs prior to the administratio phenytoin. Phenytoin was administered intravenously (Patient A-E) in doses between 10.5-20 mg/kg (mean ± S.D. = 13. 3.7) of body weight at a rate not exceeding 90 mg per minute Blood pressure and electrocardiogram were monitored durin the infusion. Lumbar puncture was performed 9 times on 6 patients and CSF specimens were obtained.
In patient E, who suffered from coma secondary to hea injury, an intraventricular catheter for continuous monitorin of intracranial pressure permitted successive assessmen CSF phenytoin concentrations. Serum specimens were obtaine at the time of the CSF collection. All serum and CSF specimen were assayed for phenytoin by gas chromatography (9).
RESULTS
Historical data and patient characteristics are listed in Tabl 1. CSF and serum concentrations are shown in Table 2 .
In all the epileptic patients treated intravenously (A-D), con vulsions ceased within 6 minutes after phenytoin administration (Laughman et al., 1976) , in which phenytoin is distri buted from a central compartment (blood) into a periphera compartment (CSF). The concentration ratio of CSF/seru phenytoin closely resembled the unbound/total serum phenytoi ration (Lund, 1972) , and suggests that free phenytoin passivel enters the CSF (Wilder et al., 1977) . However, the increase CSF/serum ratio over time suggests accumulation of fre phenytoin in the CSF against concentration gradient, withou allowing equilibration between CSF and serum unboun phenytoin.
Brain penetration of phenytoin after intravenous administra tion is rapid, and parenchymal concentration tends to excee serum levels within 20-60 minutes after infusion (Wilder et 1977; Kuttetal., 1968) . e the ratio between free/total serum phenytoin tends to stable, and there is good correlation between serum and therapeutic or toxic effects (Kutt et al., 1964) , one expect good correlation between CSF phenytoin levels clinical outcome. Indeed, in the 4 epileptic children treated I.V. phenytoin, CSF phenytoin levels were higher than 2 mcg/mg, with concomitant serum levels in the therapeutic range.
Patient G swallowed an excessive amount of phenytoin (230 kg body wt). Coma, secondary to phenytoin intoxication, correlated with the high CSF concentration of the drug (6 mcg/ml). data contradict Wilder's assumption that CSF phenytoin concentrations do not correlate with seizure control. His CSF assessments were performed on six patients who underwent pneumoencephalography. There are no details available indiwhether these patients suffered from convulsions while receiving phenytoin, nor was there any record of seizure activafter the phenytoin infusion. Moreover, in Wilder's series, phenytoin CSF concentrations ranged from 0.26-2.1 mcg/ml, than those in the epileptic children treated by us (2.1-2.8 mcg/ml). Our data suggest that phenytoin CSF levels higher mcg/ml are associated with good therapeutic outcome in children.
conclusion, CSF data may give a better idea on the real concentration of phenytoin near its target organ, thus correlatbetter than serum concentrations with the clinical outcome.
